EVOLITO-LIMITED
16.4.2024 13:07:29 CEST | Business Wire | Press release
Evolito Limited, the pioneer of world-leading axial-flux electric motors, power electronics, and battery solutions for aerospace applications, announces the appointment of Marc Holme as CTO, as it prepares for future growth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416821458/en/
Marc Holme, CTO, Evolito (Photo: Business Wire)
Marc Holme joins as CTO to lead the technology development and the future roadmap of the axial-flux e-motor and propulsion product family. He has a 24-year tenure in aviation, most recently at Collins Aerospace where he was Senior Director of Engineering. Holme’s deep technical background has seen him lead multiple aircraft system electrification programs from Airbus A380 to Boeing 787, and many technology acquisition programs.
Commenting on his appointment, Marc Holme, CTO, Evolito said:
“I’m excited to join Evolito to continue the progression towards more sustainable aviation through electrification. The advanced electric motor technology that originated for the automotive market is being adapted and improved by Evolito to enable aerospace applications where weight, efficiency and safety are critical. Combined with its leading motor control electronics and battery technologies, Evolito is well positioned to reach scalable and sustainable electric aviation.”
The new C-suite hire follows a phenomenal year for the company, having received Design Organisation Approval (DOA) from the UK Civil Aviation Authority for electric propulsion system products in December 2023. Evolito is already working with a number of OEM partners, developing motors and propulsion systems for a variety of eVTOL, Urban Air Mobility and fixed-wing applications, and expects a series of customer test flights later this year.
Dr. Chris Harris, Evolito CEO and co-founder said:
“The whole company is delighted to welcome Marc to the growing Evolito family. I’m extremely proud of what we have created here at Evolito, and our success is a reflection of our hugely talented and dedicated team, driven by a common passion for sustainable mobility. The electrification of flight is one of the most exciting market opportunities of our time, and Evolito’s innovative new technology and ability to scale means we are well positioned to meet this fast-emerging demand.”
Founded in July 2021, Evolito has grown its experienced team from 15 to over 200. It was recently awarded 2nd place in four award categories in the 2023 Best Companies100 Best Place To Work. In July 2022, Evolito acquired and later integrated Electroflight batteries into the business to offer complete propulsion solutions that are fully optimised for future aircraft applications. Amongst other partners, it works with Cranfield Aerospace Solutions who provide motor and inverters for its hydrogen aircraft demonstrator - the Fresson project.
EDITOR’S NOTES
Evolito
Evolito is making all-electric flight a reality by offering world-leading electric axial flux motors, motor control units and battery systems for the aerospace market. Evolito’s electric propulsion systems offer the highest power, torque, and energy densities in class and are inherently more robust than alternative technologies – mission critical in eVTOL, Urban Air Mobility and fixed-wing applications. The privately-held company is based in Oxford. Evolito’s investors include B-Flexion and Oxford Science Enterprises (OSE).
Marc Holme, CTO, Evolito boasts 24 years of experience in aviation and a further 5 in automotive. Prior to joining Evolito, Holme was Senior Director Engineering at Collins Aerospace. He has also worked for UTC Aerospace Systems and Goodrich. Holme has a masters in power electronics and drives from The University of Birmingham.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416821458/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom